NasdaqGM:LGNDPharmaceuticals
Evaluating Ligand Pharmaceuticals (LGND) Valuation Following $400 Million Convertible Notes Offering
If you’ve been watching Ligand Pharmaceuticals (LGND) lately, you know it has just wrapped up a $400 million convertible note offering, with new senior unsecured notes coming due in 2030. This financing move brings names like Citigroup, BofA Securities, and Stifel as co-lead underwriters, signaling that the company is making deliberate efforts to bolster its financial flexibility. For investors, a convertible bond deal of this size can indicate that Ligand is seeking resources for its...